Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DL-3-n-butylphthalide Therapy for Cerebral Hypoperfusion in Unilateral Internal Carotid System Stenosis (BUTCH)
ChiCTR2100053112Phase 4Recruiting
- Sponsor
- PLA Air Force Characteristic Medical Center
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of butylphthalide in cerebral hypoperfusion (CCH), internal carotid artery atherosclerosis (ICAS) and Ischaemic cerebral disease (2 arms), sponsored by PLA Air Force Characteristic Medical Center. Primary endpoint: Cerebral blood volume. Started Sep 2021; status: recruiting.
02
Drugs
butylphthalide
03
Conditions
cerebral hypoperfusion (CCH)internal carotid artery atherosclerosis (ICAS)Ischaemic cerebral disease
Beyond the preview
Go deeper on ChiCTR2100053112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053112.